New therapy for kidney cancer

Inlyta (axitinib) has been approved for renal cell carcinoma.  It targets many different receptors which, when engaged with specific growth factor molecules, can cause tumor growth. Inlyta attaches to these receptors and prevents tumor progression.  It is used in patients who have failed one previous therapy and has been shown to significantly extend survival.